Sucralose
drugOn this page
Also known as 1',4',6'-trichloro-galactosucrose4,1',6'-trichlorogalactosucroseAspasvitE-955INS NO.955INS-955NSC-759272San sweet sa 8020Sansweet su 100SplendaSucrazitTrichlorogalactosucroseSID144208950SID170466823
Summary
Sucralose (CHEMBL3185084) is an approved small-molecule sweetening agent; indicated across 1 condition including type 2 diabetes mellitus.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 31
- Chemistry: 397.6 Da · C12H19Cl3O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3185084 |
| Name | Sucralose |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 71485 |
| ChEBI | CHEBI:32159 |
| Molecular formula | C12H19Cl3O8 |
| Molecular weight | 397.6 |
| InChIKey | BAQAVOSOZGMPRM-QBMZZYIRSA-N |
SMILES: C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O
IUPAC name: (2R,3R,4R,5R,6R)-2-[(2R,3S,4S,5S)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol
ChEBI definition: A disaccharide derivative consisting of 4-chloro-4-deoxy-α-D-galactopyranose and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranose units linked by a glycosidic bond.
Pharmacological roles (ChEBI): sweetening agent.
Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.
Also known as: 1’,4’,6’-trichloro-galactosucrose, 4,1’,6’-trichlorogalactosucrose, Aspasvit, E-955, INS NO.955, INS-955, NSC-759272, San sweet sa 8020, Sansweet su 100, Splenda, Sucralose, Sucrazit
Patent coverage: 29,485 distinct patent families (77,857 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 9.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CA2 | 6.52 | Ki | 300 | nM | CHEMBL_ACT_18407146 |
| CA9 | 5.66 | Ki | 2200 | nM | CHEMBL_ACT_18407150 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
Clinical trials
Total trials: 31.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03407079 | PHASE2 | RECRUITING | Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study) |
| NCT01200940 | PHASE1/PHASE2 | COMPLETED | Metabolic Effects of Non-Nutritive Sweeteners |
| NCT03436277 | PHASE2 | UNKNOWN | Effect of the Administration of L-Carnitine on Body Weight in Women in Crossfit Training |
| NCT03242434 | PHASE1 | TERMINATED | Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants |
| NCT06997133 | Not specified | NOT_YET_RECRUITING | Sucralose as a Way to Enhance Regulatory T Cells |
| NCT07124585 | Not specified | NOT_YET_RECRUITING | Short-Term Effects of Sucralose and Saccharin on Blood Sugar and Gut Microbiota in Type 2 Diabetes |
| NCT07377097 | Not specified | NOT_YET_RECRUITING | Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects |
| NCT01128829 | Not specified | COMPLETED | Sugar-replacement Sweeteners, and Blood Sugar Control |
| NCT02335008 | Not specified | COMPLETED | The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot |
| NCT02335021 | Not specified | COMPLETED | The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults |
| NCT02413424 | Not specified | COMPLETED | Metabolic Effects of Non-nutritive Sweeteners |
| NCT02459535 | Not specified | COMPLETED | Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1 |
| NCT02499705 | Not specified | TERMINATED | The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents |
| NCT02589002 | Not specified | COMPLETED | Effects of Sucralose on Glucose Metabolism |
| NCT02650947 | Not specified | COMPLETED | Sucralose Effects on Glucose Metabolism and Gut Microbiota |
| NCT02745730 | Not specified | COMPLETED | RS-fMRI to Nutrient Shakes |
| NCT02800707 | Not specified | COMPLETED | Sucralose, Stevia, Gut Microbiome and Glucose Metabolism |
| NCT02813759 | Not specified | COMPLETED | Sucralose in Subjects With Diabetes Mellitus Insulin Requesting |
| NCT03247114 | Not specified | COMPLETED | fMRI of Hypothalamic Responses to Glucose, Fructose, Sucrose and Sucralose |
| NCT03680482 | Not specified | COMPLETED | To Compare the Effects of Non-nutritive Sweeteners Intake in Subjects With T2DM |
| NCT03708939 | Not specified | COMPLETED | Microbiome and Non-caloric Sweeteners in Humans |
| NCT04182464 | Not specified | COMPLETED | Effects of Sucralose in Insulin Sensitivity |
| NCT04185662 | Not specified | UNKNOWN | Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes |
| NCT04578431 | Not specified | COMPLETED | Artificial Sweeteners in Breast Milk |
| NCT04713137 | Not specified | COMPLETED | Effects of Oral Pre-loads on Subsequent Energy Intake |
| NCT05279183 | Not specified | COMPLETED | Assessment of Reward Responses to Erythritol Using Flavor Preference Learning |
| NCT05575687 | Not specified | COMPLETED | Brain and Glycemic Responses to Sweet Soft Drinks |
| NCT05810337 | Not specified | COMPLETED | Splenda: Effects on Blood Glucose Concentration, Appetite Scores and Subsequent Energy Intake |
| NCT06094894 | Not specified | COMPLETED | Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1 |
| NCT06387316 | Not specified | UNKNOWN | Cephalic Phase Responses to Nutritive and Non-Nutritive Sweeteners |
| NCT07231133 | Not specified | COMPLETED | Effect of Within-Meal Consumption of Allulose on Diet-induced Thermogenesis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: type 2 diabetes mellitus